An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole

APMIS

Volumn 107, Issue 6, 1999, Pages 566-576

  Brorson, Oystein ^a   Brorson, Sverre Henning ^b  

^a Vestfold Sentralsykehus ^*  (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Borrelia burgdorferi; Cystic forms; Metronidazole; Spheroplast; Spirochetes

Indexed keywords

METRONIDAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BORRELIA BURGDORFERI; BORRELIA INFECTION; DRUG SENSITIVITY; ERADICATION THERAPY; HELICOBACTER PYLORI; IN VITRO STUDY; INCUBATION TIME; LYME DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPHEROPLAST; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0033067423     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01594.x     Document Type: Article

References (43)

1. 1. Canica MM, Nato F, du Merle L, Mazie JC, Baranton G, Postic D. Monoclonal antibodies for identification of Borrelia afzelii sp. nov. association with late cutaneous manifestation of Lyme borreliosis. Scand J Infect Dis 1993;25:441-8.
2. 2. Bunikis J, Olsen B, Westman G, Bergstrøm S. Variable serum immunoglobulin responses against different Borrelia burgdorferi sensu lato species in a population at risk for and patients with Lyme disease. J Clin Microbiol 1995;33: 1473-8.
3. 3. Stiernstedt G. Tick-borne borrelia infection in Sweden. Scand J Infect Dis 1985; (Suppl 45): 1-70.
4. 4. Oksi J, Uksila J, Marjamäki M, Nioskelainen J, Viljanen MK. Antibodies against whole sonicated Borrelia burgdorferi spirochetes, 41-kilo-dalton flagellin, and p39 protein in patients with PCR-or culture-proven late Lyme borreliosis. J Clin Microbiol 1995;33:2260-4.
5. 5. Schutzer SE, Coyle PK, Belman AL, Golightly MG, Drulle J. Sequestration of antibody to Borrelia burgdorferi in immune complexes in sero-negative Lyme disease. Lancet 1990;335:312-5.
6. 6. Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G. Sero-logical follow-up after treatment of patients with erythema migrans and neuroborreliosis. J Clin Microbiol 1994;32:1519-25.
7. 7. Hansen K. Laboratory diagnostic methods in Lyme borreliosis. Clin Dermatol 1993;11:407-14.
8. 8. Berger BW, Johnson RC, Kodner C, Coleman L. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 1992;30:359-61.
9. 9. Stiernstedt G, Dattwyler R, Duray PH, Hansen K, Jirous J, Johnson RC, et al. Diagnostic tests in Lyme borreliosis. Scand J Infect Dis 1991;77: 136-42.
10. 10. Gasser RNA, Reisinger EC, Eber B, Wendelin I, Pokan R, Seinost G, et al. Treatment of late Lyme borreliosis with cefoperazone and sulbactam. Lancet 1995;345:586.
11. 11. Vartiovaara I. Living with Lyme. Lancet 1995; 345:842-4.
12. 12. Dattwyler RJ, Volkman DJ, Halperin JJ, Luft BJ. Treatment of late Lyme borreliosis randomised comparison of ceftriaxone and penicillin. Lancet 1988;8596:1191-4.
13. 13. Viljanen MK, Oksi J, Salomaa P, Skurnik M, Peltonen R, Kalimo H. Cultivation of Borrelia burgdorferi from the blood and a subcutaneous lesion of a patient with relapsing febrile nodular nonsuppurative panniculitis. J Infect Dis 1992; 165:596-7.
14. 14. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991;163:311-8.
15. 15. Preac Mursic V, Margot W, Busch U, Pleterski Rigler D, Hagl S. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. Infection 1996; 24:9-16.
16. 16. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme borreliosis. J Infect 1994;29:255-61.
17. 17. Preac-Mursic V, Weber K, Pfister HW, Wilske B, Gross B, Baumann A, et al. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 1989;17:355-9.
18. 18. Schmidli J, Hunziker T, Moesli P, Schaad UB. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis 1988;158: 905-6.
19. 19. Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants. Infection 1996;24:218-26.
20. 20. MacDonald AB. Concurrent neocortical borreliosis and Alzheimer's disease. Ann NY Acad Sci 1988;539:468-70.
21. 21. Hulínská D, Barták P, Hercogová J, Hancil J, Basta J, Schramlová J. Electron microscopy of Langerhans cells and Borrelia burgdorferi in Lyme disease patients. Int J Med Microbiol Virol Parasitol Infect Dis 1994;280:348-59.
22. 22. Kersten A, Poitschek S, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother 1995;39:1127-33.
23. 23. Burgdorfer W, Hayes SF. Vector-spirochete relationship in louse-borne and tick-borne borreliosis with emphasis on Lyme disease. In: Harris KF, editor. Advances in Disease Vector Research. Vol 6. Springer, New York 1989, 127-50.
24. 24. Schaller M, Neubert U. Ultrastructure of Borrelia burgdorferi after exposure to benzylpenicillin. Infection 1994;22:401-6.
25. 25. Brorson Ø, Brorson SH. Transformation of cystic forms of Borrelia burgdorferi to normal mobile spirochetes. Infection 1997;25:240-6.
26. 26. Brorson Ø, Brorson SH. In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. Infection 1998;26:144-50.
27. 27. Brorson Ø, Brorson SH. A rapid method for generating cystic forms of Borrelia burgdorferi and their reversal to mobile spirochetes. APMIS 1998;106:1131-41.
28. 28. Lacey SL, Moss SF, Taylor GW Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori. J Antimicrob Chemother 1993;32:393-400.
29. 29. Muller M, Gorrell TE. Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities. Antimicrob Agents Chemother 1983;24:667-73.
30. 30. Cedeno JR, Krogstad DJ. Susceptibility testing of Entamoeba histolytica. J Infect Dis 1983; 148:1090-5.
31. 31. Åsbrink E, Hovmark A, Hederstedt B. The spirochetal etiology of acrodermatitis chronica atropicans Herxheimer. Acta Derm Venerol 1984; 64:506-12.
32. 32. Pollack RJ, Telford SR, Spielman A. Standardization of medium for culturing Lyme disease spirochetes. J Clin Microbiol 1993;31:1251-5.
33. 33. Jobe DA, Callister SM, Schell RF. Recovery of Borrelia burgdorferi by filtration. J Clin Microbiol 1993;31:1896-7.
34. 34. Brorson SH, Skjørten F. Mechanism for antigen detection on deplasticized epoxy sections. Micron 1995;26:301-10.
35. 35. Brorson SH, Strøm EH, Skjørten F. Immunoelectron microscopy on epoxy sections without deplasticizing to detect glomerular immunoglobulin and complement deposits in renal diseases. APMIS 1997;105:139-49.
36. 36. Lim LCL, Liu YF, Schell K, Lovrich SD, Callister SM, Schell RF. Detection of borreliacidal antibody by using acridine orange and flow cytometry. Clin Diagn Lab Immunol 1994;1:44-50.
37. 37. Miliotis MD. Acridine orange stain for determining intracellular enteropathogens in HeLa cells. J Clin Microbiol 1991;29:830-1.
38. 38. Whitehouse CA, Williams LR, Austin FE. Identification of superoxide dismutase activity in Borrelia burgdorferi. Infect Immun 1997;65: 4865-8.
39. 39. Reisinger E, Werdelin I, Gasser R, Halwachs G, Wilders-Trusching M, Krejs G. Antibiotics and increased temperature against Borrelia burgdorferi in vitro. Scand J Infect Dis 1996;28:155-7.
40. 40. Dever LL, Jorgensen JH, Barbour AG. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 1993;37:1115-21.
41. 41. Andersen AP, Elliott DA, Lawson M, Barland P, Hatcher VB, Puszkin EG. Growth and morphological transformation of Helicobacter pylori in broth media. J Clin Microbiol 1997;35:2918-22.
42. 42. Ma Y, Seiler KP, Tai KF, Yang L, Woods M, Weis JJ. Outer Surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by the cytokine-inducible pathway. Infect Immun 1994; 62:3663-71.
43. 43. Samuels DS, Garon CF. Coumermycin A1 inhibits growth and induces relaxation of supercoiled plasmids in Borrelia burgdorferi, the Lyme disease agent. Antimicrob Agents Chemother 1993;37:46-50.